Results 211 to 220 of about 836,777 (260)

Molecular taxonomy of pancreatic neuroendocrine tumors reveals BEND2-fusions-driven transcriptional plasticity and therapeutic vulnerabilities. [PDF]

Cell Rep Med
Lu X, Baltzinger P, Xu L, Fattori A, Bazai SK, Alhourani F, Chenard MP, Bachellier P, Addeo P, Debien V, Vacheret C, Imperiale A, Pessaux P, Cheng W, Balzinger M, Kurtz JE, Davidson I, Su X, Goichot B, Malouf GG.   +19 more
europepmc   +1 more source

Diagnosis and Management of Functional Pancreatic Neuroendocrine Tumors in Children-A Systematic Review. [PDF]

Diagnostics (Basel)
Keretić D, Bašković M.
europepmc   +1 more source

[Neuroendocrine pancreatic tumor].

Gaceta medica de Mexico, 2001
R, Gerson, A, Serrano, C, Ortiz-Hidalgo, M, Gómez-Palacio, R, Chiprut, A, Villalobos   +5 more
openaire   +1 more source

New sights of spleen-preserving versus splenectomy in distal pancreatectomy for pancreatic neuroendocrine tumors: a systematic review and meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Liu H, Wei K, Cao R, Yang S, Wang F, Zhang S, Wu J, Feng Z, Zhou C, Wu S, Han L, Wang Z, Ma Q, Wu Z.   +13 more
europepmc   +1 more source

Gender Differences in Prognosis of Pancreatic Neuroendocrine Tumors: A Retrospective Cohort Study Based on the SEER Database. [PDF]

Cancer Control
Li Y, Zhou S, Qiao Q, Ji K, Li Q, Qiao Z, Zhang P.   +6 more
europepmc   +1 more source

Secretogranin II serves as a potential prognostic biomarker and correlates with the immune microenvironment in pancreatic neuroendocrine tumors. [PDF]

Transl Cancer Res
Yang W, Xu L, Li H, Wang S, Guo H, Zhang J, Peng L.   +6 more
europepmc   +1 more source

Efficacy and safety of EUS-guided radiofrequency ablation in pancreatic neuroendocrine tumors: A systematic review and meta-analysis. [PDF]

Endosc Ultrasound
Bidani K, Moond V, Harne PS, Ali H, Paladiya R, Mohan BP, Broder A, Thosani N, Adler DG.   +8 more
europepmc   +1 more source

GSK3i combinatorial treatments affect CDK4/6 and compensatory pathways in 3D preclinical models of pancreatic neuroendocrine tumors. [PDF]

Biol Open
Luca E, Shapiro I, Debaix H, Zitzmann K, Wang K, Auernhammer CJ, Beuschlein F, Nölting S, Hantel C.   +8 more
europepmc   +1 more source

Circulating Gene Expression Assay as a Diagnostic and Prognostic Biomarker for Pancreatic Neuroendocrine Tumors in MEN1.

J Clin Endocrinol Metab
van Vliembergen ENM, van Treijen MJC, van Leeuwaarde RS, Pieterman CRC, de Laat JM, Tesselaar MET, Valk GD.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Management of Pancreatic Neuroendocrine Tumors

Surgical Clinics of North America, 2013
Pancreatic neuroendocrine tumors account for 1% to 2% of pancreatic neoplasms and may occur sporadically or as part of a hereditary syndrome. Patients may present with symptoms related to hormone secretion by functional tumors or to locally advanced or metastatic nonfunctional tumors.
Paxton V Dickson, Stephen W Behrman
exaly   +3 more sources